140 related articles for article (PubMed ID: 11489662)
1. Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
Avalos M; Mak C; Randall PK; Trzeciakowski JP; Abell C; Kwan SW; Wilcox RE
J Pharmacol Toxicol Methods; 2001; 45(1):17-37. PubMed ID: 11489662
[TBL] [Abstract][Full Text] [Related]
2. Improved models for pharmacological null experiments: calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines.
Mak CK; Avalos M; Randall PK; Kwan SW; Abell CW; Neumeyer JL; Whisennand R; Wilcox RE
Neuropharmacology; 1996 May; 35(5):549-70. PubMed ID: 8887963
[TBL] [Abstract][Full Text] [Related]
3. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
4. D1 dopamine receptor activity of anti-parkinsonian drugs.
Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
6. Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors.
Zackheim JA; Abercrombie ED
Brain Res Bull; 2001 Apr; 54(6):603-7. PubMed ID: 11403986
[TBL] [Abstract][Full Text] [Related]
7. Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors?
Jackson DM; Wikström H; Liao Y
Psychopharmacology (Berl); 1998 Jul; 138(2):213-6. PubMed ID: 9718292
[No Abstract] [Full Text] [Related]
8. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
9. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
10. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
[TBL] [Abstract][Full Text] [Related]
11. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors.
Cheung TH; Bezzina G; Hampson CL; Body S; Fone KC; Bradshaw CM; Szabadi E
Psychopharmacology (Berl); 2007 Dec; 195(2):213-22. PubMed ID: 17668188
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.
O'Neill MJ; Hicks CA; Ward MA; Cardwell GP; Reymann JM; Allain H; Bentué-Ferrer D
Eur J Pharmacol; 1998 Jul; 352(1):37-46. PubMed ID: 9718265
[TBL] [Abstract][Full Text] [Related]
14. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat.
Wachtel SR; Brooderson RJ; White FJ
Psychopharmacology (Berl); 1992; 109(1-2):41-8. PubMed ID: 1365670
[TBL] [Abstract][Full Text] [Related]
15. Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits.
Prünte C; Nuttli I; Markstein R; Kohler C
J Neural Transm (Vienna); 1997; 104(2-3):111-23. PubMed ID: 9203075
[TBL] [Abstract][Full Text] [Related]
16. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
17. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
[TBL] [Abstract][Full Text] [Related]
19. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
[TBL] [Abstract][Full Text] [Related]
20. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
